XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3
EQUITY (Tables)
9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK

 

   Number of
underlying
Common stock
   Exercise price   Expiration date 
Series F Warrants   433,878   $7.4250    June 5, 2025-October 16, 2025 
Series G Warrants   1,092,344   $10.230    February 8, 2026 
Series I Warrants   12,914,078   $1.3827    * 
Series J Warrants   12,914,086   $1.3827    * 
Series K Warrants   12,914,078   $1.3827    * 
Total Warrants   40,268,464           

 

  * The Warrants have a term of the earlier of (i) May 15, 2028 and (ii) (A) in the case of the Series I Warrants, 20 trading days following the Company’s announcement of receipt of Premarket Approval from the Food and Drug Administration (“FDA”) for the CGuard Prime Carotid Stent System (135 cm), (B) in the case of the Series J Warrants, 20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 and (C) in the case on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begins.